[Positron emission tomography of the thorax. The current clinical status].
The non-invasive diagnostic assessment of thoracic lesions has been greatly enhanced by the use of positron emission tomography with metabolic active radio-compounds such as fluor-18 labeled deoxyglucose. Four clinical fields of use were established: differential diagnostic evaluation of lesions (T-staging); classification of adenopathy (N-staging); therapy response monitoring; diagnostic evaluation of recurrence. The upcoming challenges for clinical use are limited availability and necessary technical and qualitative standardizations.
Knopp
M V
MV
Forschungsschwerpunkt Radiologische Diagnostik und Therapie, Deutsches Krebsforschungszentrum, Heidelberg.
Bischoff
H
H
Oberdorfer
F
F
van Kaick
G
G
D002283:Carcinoma, Bronchogenic / Q000000981:diagnostic imaging*; D003847:Deoxyglucose / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging*; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed / Q000379:methods*
D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose
Positronenemissionstomographie des Thorax. Derzeitiger klinischer Stellenwert.